Post on 07-Apr-2018
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 1/65
DR FAIZA GHUMAN
RESIDENT, MED 4,CHK.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 2/65
37 yo moderately obese female onOCP presents to ER with a two dayhistory of painless R leg swelling.She’s been elevating her leg several
days after a severe ankle sprain duringa mother-daughter soccer game.
No prior medical history, recentsurgery or weight loss. She is a non-smoker and drinks rarely.
Exam is notable for R ankle splint andpitting edema in R calf, which is 1.5 cmlarger than the L.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 3/65
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 4/65
Deep vein thrombosis is theformation of a blood clot in one ofthe deep veins of the body, usually
in the leg
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 5/65
DVT ususally originates in the lowerextremity venous level ,starting at the calf
vein level and progressing proximally toinvolve popliteal ,femoral ,or iliac system. .80-90 % pulmonary emboli originates here .
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 6/65
More than 100 years ago, Virchow described atriad of factors of
venous stasis, endothelial damage, and hypercoagulable state
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 7/65
General- Age- Immobilization > 3d- Pregnancy / post-partum
- Major surgery < 4 weeks- Trip (>4h) in past 4 weeks
Medical- Cancer- Previous DVT
- CHF- Sepsis- Nephrotic syndrome
Trauma- CNS / spinal cord injury- Burns- Lower extremity fractures
Hematologic- Thrombocytosis- Anti-thrombin III deficiency- Protein C deficiency- Protein S deficiency
- Factor V Leiden Drugs
- OCP- Estrogens
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 8/65
Inflammatory processes, such as• systemic lupus erythematosus (SLE),
• sickle cell disease, and•inflammatory bowel disease (IBD),
also predispose to thrombosis, presumably due tohypercoagulability
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 9/65
Trauma, surgery, and invasive procedure may disrupt venous
integrity Iatrogenic causes of venous thrombosis are
increasing due to the widespread use of
central venous catheters, particularlysubclavian and internal jugular lines. Theselines are an important cause of upperextremity DVT, particularly in children.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 10/65
Calf pain or tenderness, or both Swelling with pitting oedema Swelling below knee in distal deep vein
thrombosis and up to groin in proximal deepvein thrombosis
Increased skin temperature
Superficial venous dilatation Cyanosis can occur with severe obstruction
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 11/65
Palpate distal pulses and evaluate capillaryrefill to assess limb perfusion.
Move and palpate all joints to detect acutearthritis or other joint pathology.
Neurologic evaluation may detect nerve rootirritation; sensory, motor, and reflex deficits
should be noted Homans'’ sign: pain in the posterior calf or
knee with forced dorsiflexion of the foot
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 12/65
Search for stigmata of PE such as tachycardia(common), tachypnea or chest findings (rare),
and exam for signs suggestive of underlying
predisposing factors.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 13/65
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 14/65
Clinical Parameter Score
Active cancer +1
Paralysis or recent immobilization of extremities +1
Recently bedridden for > 3 days or major surgery <4 weeks +1
Tenderness along distribution of deep venous system +1
Entire leg swollen +1
Calf swelling > 3cm circumference difference from unaffected leg +1
Pitting edema +1
Previous DVT +1
Collateral superficial veins +1
Alternative diagnosis as likely or more likely than DVT -2
High Probability ≥ 3
Moderate Probability 1 or 2
Low Probabillity 0
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 15/65
D-dimer is a specific degradation product of cross-linked fibrin. Because concurrentproduction and breakdown of clot
characterize thrombosis, patients withthromboembolic disease have elevated levelsof D-dimer
three major approaches for measuring D-
dimer ELISA latex agglutination blood agglutination test (SimpliRED
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 16/65
False-positive D-dimers occur in patients with recent (within 10 days) surgery or trauma, recent myocardial infarction or stroke, acute infection, disseminated intravascular coagulation, pregnancy or recent delivery,
active collagen vascular disease, ormetastatic cancer
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 17/65
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 18/65
Study Notes
Contrast Venography - “Gold standard”, 99% sensitive- Allergic reaction, availability,IV contrast, costly
- Good for calf, iliac veins, IVC
MRI - Useful in pregnancy- Can distinguish acute from chronic- Good for calf, iliac veins- Cost, accessibility
CT - Can do PE study at same time
- Good for calf, iliac veinsDuplex Ultrasonography - No radiation, bedside, cost
- Non-occlusive thrombi- Cannot distinguish acute from chronic- Poor visualization of calf, iliac veins
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 19/65
Invasive venography,
radiolabeled fibrinogen and. noninvasiveultrasound,plethysmography,MRI techniques
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 20/65
gold standard” modality for the diagnosis of DVT
Advantages Venography is also useful if the patient has a
high clinical probability of thrombosis and anegative ultrasound,
it is also valuable in symptomatic patientswith a history of prior thrombosis in whomthe ultrasound is non-diagnostic.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 21/65
phlebitis anaphylaxis
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 22/65
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 23/65
Because the radioactive isotope incorporatesinto a growing thrombus, this test candistinguish new clot from an old clot
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 24/65
Plethysmography measures change in lowerextremity volume in response to certain
stimuli.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 25/65
color-flow Duplex scanning is the imagingtest of choice for patients with suspected
DVT inexpensive, noninvasive, widely available Ultrasound can also distinguish other causes
of leg swelling, such as tumor, popliteal cyst,abscess, aneurysm, or hematoma.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 26/65
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 27/65
expensive reader dependent
Duplex scans are less likely to detect non-occluding thrombi. During the second half of pregnancy,
ultrasound becomes less specific, becausethe gravid uterus compresses the inferiorvena cava, thereby changing Doppler flow inthe lower extremities
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 28/65
It detects leg, pelvis, and pulmonary thrombiand is 97% sensitive and 95% specific for DVT. It distinguishes a mature from an immature
clot. MRI is safe in all stages of pregnancy.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 29/65
Cellulitis Thrombophlebitis Arthritis
Asymmetric peripheral edema secondary to CHF,liver disease, renal failure, or nephrotic syndromelymphangitis
Extrinsic compression of iliac vein secondary to
tumor, hematoma, or abscess Hematoma Lymphedema
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 30/65
Muscle or soft tissue injury Neurogenic pain Postphlebitic syndrome Prolonged immobilization or limb paralysis
Ruptured Baker cyst Stress fractures or other bony lesions
Superficial thrombophlebitis Varicose veins
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 31/65
Using the pretest probability score calculatedfrom the Wells Clinical Prediction rule,patients are stratified into 3 risk groups—high, moderate, or low.
The results from duplex ultrasound areincorporated as follows:
If the patient is high or moderate risk and theduplex ultrasound study is positive, treat forDVT.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 32/65
If the duplex study is negative and the patientis low risk, DVT has been ruled out.
• When discordance exists between the pretestprobability and the duplex study result,further evaluation is required.
If the patient is high risk but the ultrasound
study was negative, the patient still has asignificant probability of DVT
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 33/65
a venogram to rule out a calf vein DVT surveillance with repeat clinical evaluation
and ultrasound in 1 week. results of a D-dimer assay to guide
management If the patient is low risk but the ultrasound
study is positive, some authors recommend asecond confirmatory study such as avenogram before treating for DVT
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 34/65
The primary objectives of the treatment of DVT are to
prevent pulmonary embolism, reduce morbidity, and prevent or minimize the risk of developing
the postphlebitic syndrome.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 35/65
Anticoagulation Thrombolytic therapy for DVT
Surgery for DVT Filters for DVT Compression stockings
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 36/65
Heparin prevents extension of the thrombus Heparin's anticoagulant effect is related
directly to its activation of antithrombin III.Antithrombin III, the body's primaryanticoagulant, inactivates thrombin andinhibits the activity of activated factor X in
the coagulation process.
Heparin is a heterogeneous mixture of
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 37/65
Heparin is a heterogeneous mixture of polysaccharide fragments with varyingmolecular weights but with similar biological
activity. The larger fragments primarilyinteract with antithrombin III to inhibitthrombin.
The low molecular weight fragments exerttheir anticoagulant effect by inhibiting theactivity of activated factor X. The
hemorrhagic complications attributed toheparin are thought to arise from the largerhigher molecular weight fragments.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 38/65
The optimal regimen for the treatment of DVT is anticoagulation with heparin or an
LMWH followed by full anticoagulation withoral warfarin for 3-6 months Warfarin therapy is overlapped with heparin
for 4-5 days until the INR is therapeutically
elevated to between 2-3.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 39/65
After an initial bolus of 80 U/kg, a constantmaintenance infusion of 18 U/kg is initiated.
The aPTT is checked 6 hours after the bolusand adjusted accordingly. . The aPTT is repeated every 6 hours until 2
successive aPTTs are therapeutic. Thereafter,
the aPTT is monitored every 24 hours as wellas the hematocrit and platelet count.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 40/65
Superior bioavailability Superior or equivalent safety and efficacy Subcutaneous once- or twice-daily dosing No laboratory monitoring* Less phlebotomy (no monitoring/no intravenous
line) Less thrombocytopenia Earlier/facilitated
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 41/65
At the present time, 3 LMWH preparations, Enoxaparin,
Dalteparin, and Ardeparin
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 42/65
Interferes with hepatic synthesis of vitaminK-dependent coagulation factors
Dose must be individualized and adjusted tomaintain INR between 2-3 2-10 mg/d PO caution in active tuberculosis or diabetes;
patients with protein C or S deficiency are atrisk of developing skin necrosis
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 43/65
Advantages include prompt resolution of symptoms,
prevention of pulmonary embolism, restoration of normal venous circulation, preservation of venous valvular function, and prevention of postphlebitic syndrome.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 44/65
Thrombolytic therapy does not prevent clot propagation,
rethrombosis, or subsequent embolization. Heparin therapy and oral anticoagulant
therapy always must follow a course of
thrombolysis.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 45/65
Thrombolytic therapy is also not effective once the
thrombus is adherent and begins to organize The hemorrhagic complications of thrombolytic
therapy are formidable (about 3 times higher),
including the small but potentially fatal risk of intracerebral hemorrhage.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 46/65
indications when anticoagulant therapy is ineffective
unsafe, contraindicated. The major surgical procedures for DVT are
clot removal and partial interruption of the
inferior vena cava to prevent pulmonaryembolism.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 47/65
These pulmonary emboli removed at autopsy look
like casts of the deep veins of the leg where theyoriginated.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 48/65
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 49/65
Indications for insertion of an inferior venacava filter
Pulmonary embolism with contraindicationto anticoagulation Recurrent pulmonary embolism despite
adequate anticoagulation
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 50/65
Controversial indications: Deep vein thrombosis with contraindication
to anticoagulation Deep vein thrombosis in patients with pre-
existing pulmonary hypertension Free floating thrombus in proximal vein
Failure of existing filter device Post pulmonary embolectomy
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 51/65
Inferior vena cava filters reduce the rate of pulmonary embolism but have no effect on
the other complications of deep veinthrombosis. Thrombolysis should beconsidered in patients with major proximalvein thrombosis and threatened venous
infarction
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 52/65
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 53/65
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 54/65
Most patients with confirmed proximal vein DVTmay be treated safely on an outpatient basis.Exclusion criteria for outpatient management are as
follows: Suspected or proven concomitant pulmonary
embolism Significant cardiovascular or pulmonary
comorbidity Morbid obesity Renal failure
Unavailable or unable to arrange close follow-up
Patients are treated with a low molecular weight
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 55/65
Patients are treated with a low molecular weightheparin and instructed to initiate therapy withwarfarin 5 mg PO the next day. Low molecular
weight heparin and warfarin are overlapped forabout 5 days until the international normalizedratio (INR) is therapeutic.
If inpatient treatment is necessary, low molecularweight heparin is effective and obviates the needfor IV infusions or serial monitoring of the PTT.
With the introduction of low molecular weightheparin, selected patients qualify for outpatienttreatment only if adequate home care and closemedical follow-up care can be arranged.
Platelets also should be monitored and heparin
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 56/65
Platelets also should be monitored and heparindiscontinued if platelets fall below 75,000.
While on warfarin, the prothrombin time (PT) must
be monitored daily until target achieved, thenweekly for several weeks. When the patient isstable, monitor monthly.
Significant bleeding (ie, hematemesis, hematuria,gastrointestinal hemorrhage) should beinvestigated thoroughly since anticoagulant
therapy may unmask a preexisting disease (eg,cancer, peptic ulcer disease, arteriovenousmalformation).
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 57/65
Transient cause and no other risk factors: 3 months Idiopathic: 3-6 months Ongoing risk for example, malignancy: 6 -12 months Recurrent pulmonary embolism or deep vein
thrombosis: 6-12 months Patients with high risk of recurrent thrombosis
exceeding risk of anticoagulation: indefiniteduration (subject to review)
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 58/65
Patients with suspected or diagnosedisolated calf vein DVT may be dischargedsafely on a nonsteroidal anti-inflammatory
drug (NSAID) or aspirin with close follow-upcare and repeat diagnostic studies in 3-7 daysto detect proximal extension.
At certain centers, patients with isolated calf vein DVT are admitted for full anticoagulanttherapy.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 59/65
Patients with suspected DVT but negativenoninvasive studies need to be reassessed bytheir primary care provider within 3-7 days.
Patients with ongoing risk factors may needto be restudied at that time to detectproximal extension because of the limited
accuracy of noninvasive tests for calf veinDVT.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 60/65
Acute pulmonary embolism Hemorrhagic complications Chronic venous insufficiency
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 61/65
All patients with proximal vein DVT are at
long-term risk of developing chronic venousinsufficiency.
About 20% of untreated proximal (above thecalf) DVTs progress to pulmonary emboli,and 10-20% of these are fatal. Withaggressive anticoagulant therapy, the
mortality is decreased 5- to 10-fold. DVT confined to the calf virtually never
causes clinically significant emboli and thusdoes not require anticoagulation
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 62/65
Advise women taking estrogen of the risks
and common symptoms of thromboembolicdisease.
Discourage prolonged immobility,particularly on plane rides and long car trips
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 63/65
Ideidentify any patiant who is at risk. Prevent dehydration. During operation avoid prolonged calf compression. Passive leg exercises should be encourged whilst
patient on bed. Foot of bed should be elevated to increase venous
return.
Early mobilization should be rule for all surgicalpatients.
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 64/65
8/4/2019 dvt_2 faiza
http://slidepdf.com/reader/full/dvt2-faiza 65/65
THANK YOU